Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.73 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.73 |
| ▸ | GAA | P10253 | 2/20 | 0.73 |
| ▸ | POLB | P06746 | 1/20 | 0.69 |
| ▸ | LMNA | P02545 | 3/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.64 |
| ▸ | HPGD | P15428 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | CA1 | P00915 | 1/20 | 0.62 |
| ▸ | CA2 | P00918 | 1/20 | 0.62 |
| ▸ | CA9 | Q16790 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.61 |
| ▸ | MRGPRX1 | Q96LB2 | 2/20 | 0.61 |
| ▸ | F2 | P00734 | 1/20 | 0.61 |
| ▸ | F10 | P00742 | 1/20 | 0.61 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.61 |
| ▸ | F7 | P08709 | 1/20 | 0.61 |
| ▸ | KIT | P10721 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10119775 | 0.91 | MAPT (0.74) | MAPTALDH1A1KDM4ETDP1GAA | |
| SCHEMBL3410940 | 0.89 | MAPT (0.65) | MAPTALDH1A1KDM4ETDP1GAA | |
| SCHEMBL31192466 | 0.88 | MRGPRX1 (0.74) | MAPTALDH1A1KDM4ETDP1GAA | |
| SCHEMBL10119743 | 0.88 | MAPT (0.71) | MAPTALDH1A1KDM4ETDP1GAA | |
| SCHEMBL2711213 | 0.85 | MAPT (0.68) | MAPTALDH1A1KDM4ETDP1GAA | |
| SCHEMBL16057469 | 0.85 | GAA (0.64) | MAPTALDH1A1KDM4ETDP1GAA | |
| SCHEMBL28610112 | 0.85 | MAPT (1.00) | MAPTALDH1A1KDM4ETDP1GAA | |
| SCHEMBL8065663 | 0.83 | MAPT (0.74) | MAPTALDH1A1KDM4ETDP1GAA | |
| SCHEMBL28039966 | 0.83 | MAPT (0.74) | MAPTALDH1A1KDM4ETDP1GAA | |
| SCHEMBL5309365 | 0.83 | HIF1A (0.63) | MAPTALDH1A1KDM4ETDP1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9725439-B2 | Quinazoline derivative and preparation method therefor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2017-08-08 | — | — | US | disclosed |
| WO-2015043515-A1 | QUINAZOLINE DERIVATIVE AND PREPARATION METHOD THEREFOR | 正大天晴药业集团股份有限公司 | 2015-04-02 | — | — | WO | disclosed |
| US-7329761-B2 | Substituted imides | CELGENE CORPORATION (US) | 2008-02-12 | — | — | US | disclosed |
| EP-0800514-B1 | SUBSTITUTED IMIDES AS TNF INHIBITORS | CELGENE CORP (US) | 2006-08-23 | — | — | EP | disclosed |
| US-20050090516-A1 | Novel substituted imides | MULLER GEORGE W (US) | 2005-04-28 | — | — | US | disclosed |
| US-6844359-B2 | Substituted imides | CELGENE CORPORATION (US) | 2005-01-18 | — | — | US | disclosed |
| US-20020143027-A1 | Novel substituted imides | MULLER GEORGE W (US) | 2002-10-03 | — | — | US | disclosed |
| US-6429221-B1 | INHIBITORS OF TUMOR NECROSIS FACTOR; USED TO TREAT CACHEXIA, ENDOTOXIC SHOCK, AND RETROVIRUS REPLICATION | CELGENE CORPORATION | 2002-08-06 | — | — | US | disclosed |
| EP-0800514-A1 | SUBSTITUTED IMIDES AS TNF INHIBITORS | CELGENE CORPORATION (US) | 1997-10-15 | — | — | EP | disclosed |
| WO-1996020926-A9 | SUBSTITUTED IMIDES AS TNF INHIBITORS | — | 1996-09-26 | — | — | WO | disclosed |
| WO-1996020926-A1 | SUBSTITUTED IMIDES AS TNF INHIBITORS | CELGENE CORPORATION (US) | 1996-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143027-A1 | Novel substituted imides | TNF, MIF, TNFRSF1A | MAPT 4400/4885ALDH1A1 3516/4885KDM4E 276/4885 |
| US-20050090516-A1 | Novel substituted imides | TNF, MIF, TNFRSF1A | MAPT 4293/4885ALDH1A1 3735/4885KDM4E 241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.